__NUXT_JSONP__("/drugs/Cabozantinib", (function(a,b,c,d){return {data:[{drug:{slug:a,emaEpar:[{activeSubstance:b,conditionIndication:"Treatment of adult patients with progressive, unresectable locally advanced or metastatic medullary thyroid carcinoma.",inn:b,marketingAuthorisationDate:"2014-03-21 01:00:00",marketingAuthorisationHolder:c,medicineName:"Cometriq",url:"https:\u002F\u002Fwww.ema.europa.eu\u002Fen\u002Fmedicines\u002Fhuman\u002FEPAR\u002Fcometriq"},{activeSubstance:"cabozantinib (s)-malate",conditionIndication:"Renal Cell Carcinoma (RCC)Cabometyx is indicated as monotherapy for the treatment of advanced renal cell carcinoma (RCC):in treatment-naïve adults with intermediate or poor risk,in adults following prior vascular endothelial growth factor (VEGF)-targeted therapy.Cabometyx, in combination with nivolumab, is indicated for the first-line treatment of advanced renal cell carcinoma in adults.Hepatocellular Carcinoma (HCC)Cabometyx is indicated as monotherapy for the treatment of hepatocellular carcinoma (HCC) in adults who have previously been treated with sorafenib.",inn:b,marketingAuthorisationDate:"2016-09-09 00:00:00",marketingAuthorisationHolder:c,medicineName:"Cabometyx ",url:"https:\u002F\u002Fwww.ema.europa.eu\u002Fen\u002Fmedicines\u002Fhuman\u002FEPAR\u002Fcabometyx"}],fdaDrugLabel:[],id:a,nciThesaurus:{casRegistry:"849217-68-1",chebiId:"",chemicalFormula:"C28H24FN3O5",definition:"An orally bioavailable, small molecule receptor tyrosine kinase (RTK) inhibitor with potential antineoplastic activity. Cabozantinib strongly binds to and inhibits several RTKs, which are often overexpressed in a variety of cancer cell types, including hepatocyte growth factor receptor (MET), RET (rearranged during transfection), vascular endothelial growth factor receptor types 1 (VEGFR-1), 2 (VEGFR-2), and 3 (VEGFR-3), mast\u002Fstem cell growth factor (KIT), FMS-like tyrosine kinase 3 (FLT-3), TIE-2 (TEK tyrosine kinase, endothelial), tropomyosin-related kinase B (TRKB) and AXL. This may result in an inhibition of both tumor growth and angiogenesis, and eventually lead to tumor regression.",fdaUniiCode:"1C39JW444G",identifier:"C52200",preferredName:a,semanticType:"Pharmacologic Substance",subclassOf:["C143099","C159438","C93259"],synonyms:["1,1-Cyclopropanedicarboxamide, N'-[4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-N-(4- fluorophenyl)-","CABOZANTINIB",a,"N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N'-(4-fluorophenyl)cyclopropane-1,1- dicarboxamide"]},dir:"\u002Fdrugs",path:"\u002Fdrugs\u002FCabozantinib",extension:".json",createdAt:d,updatedAt:d}}],fetch:{},mutations:void 0}}("Cabozantinib","cabozantinib","Ipsen Pharma","2021-10-30T13:40:36.523Z")));